Examkin

Soru

Zorluk: Çok zorInfectious Diseases

A 36-year-old man with a history of advanced, untreated HIV infection (CD4 count 28 cells/mm328 \text{ cells/mm}^3) is brought to the emergency department due to progressive confusion, severe headaches, and left-sided weakness over the past week. His temperature is 38.1∘C38.1^\circ\text{C} (100.6∘F100.6^\circ\text{F}). Neurologic examination reveals a dense left hemiparesis. MRI of the brain reveals multiple 1- to 2-cm ring-enhancing lesions in the right basal ganglia and frontal lobe with marked surrounding vasogenic edema causing a 4-mm midline shift. Serum *Toxoplasma gondii* IgG antibodies are positive.

Arrange the following clinical actions in the correct chronological sequence according to the standard management algorithm for this patient, assuming a complete lack of clinical or radiographic response to the first-line medical intervention.

  1. 1Start empiric pyrimethamine, sulfadiazine, and leucovorin
  2. 2Obtain a repeat brain MRI at 10 to 14 days to assess for lesion regression
  3. 3Consult neurosurgery for a stereotactic brain biopsy
  4. 4Send biopsied tissue for Epstein-Barr virus (EBV) DNA polymerase chain reaction
  5. 5Consult oncology for initiation of high-dose methotrexate

Cevap

The correct sequence is to first start empiric toxoplasmosis therapy, follow up with a repeat brain MRI in 10-14 days to check for response, perform a stereotactic brain biopsy when there is no improvement, test the tissue for EBV DNA to confirm lymphoma, and finally initiate high-dose methotrexate therapy.
In patients with advanced HIV (CD4 < 100 cells/mm³) presenting with multiple ring-enhancing brain lesions and positive Toxoplasma serology, the standard of care is to initiate an empiric trial of anti-Toxoplasma therapy (pyrimethamine, sulfadiazine, and leucovorin). Because these lesions frequently cause marked vasogenic edema and mass effect, early lumbar puncture is contraindicated due to the risk of cerebral herniation. The clinical and radiographic response to this empiric trial is assessed via repeat MRI in 10 to 14 days. If the lesions do not regress or if the patient worsens, the diagnosis of Toxoplasma encephalitis becomes highly unlikely. At this juncture, primary central nervous system lymphoma (PCNSL)—the second most common cause of ring-enhancing lesions in HIV—becomes the primary differential diagnosis. A stereotactic brain biopsy is then indicated to establish a definitive tissue diagnosis. In HIV patients, PCNSL is almost universally an AIDS-defining malignancy driven by Epstein-Barr virus (EBV), which can be identified in the biopsied tissue via PCR or in-situ hybridization. Upon confirmation of PCNSL, the first-line targeted treatment is systemic chemotherapy utilizing high-dose methotrexate.

Adım Adım Çözüm

1
Evaluate the patient's initial presentation and infectious risk profile.
The patient has advanced HIV, multiple ring-enhancing lesions, and positive Toxo serology, pointing to Toxoplasma encephalitis.
Toxoplasmosis is the most common cause of focal brain lesions in HIV patients with CD4 < 100 cells/mm³.
2
Determine the first therapeutic intervention.
Initiate empiric pyrimethamine, sulfadiazine, and leucovorin.
Immediate medical treatment is required. Brain biopsy and lumbar puncture are deferred initially due to the high probability of toxoplasmosis and contraindications (mass effect risk for herniation).
3
Establish the follow-up interval for the empiric trial.
Perform a repeat brain MRI in 10 to 14 days.
To determine if the empiric trial is successful. A complete lack of clinical or radiographic response strongly indicates an alternative diagnosis.
4
Identify the next procedural step for treatment failure.
Consult neurosurgery for a stereotactic brain biopsy.
Failure of empiric therapy shifts the most likely diagnosis to Primary Central Nervous System Lymphoma (PCNSL), which requires definitive tissue confirmation before starting chemotherapy.
5
Confirm the alternative diagnosis pathologically.
Send biopsied tissue for EBV DNA testing.
PCNSL in immunocompromised patients is almost universally driven by Epstein-Barr virus (EBV).
6
Select the targeted therapy for the confirmed diagnosis.
Initiate high-dose methotrexate.
This is the first-line systemic chemotherapy standard of care for Primary CNS Lymphoma.

Anahtar Kavram

Algorithm for differentiating and managing Toxoplasma encephalitis versus Primary Central Nervous System Lymphoma in patients with advanced HIV.
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru